Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Once-yearly diabetes drug

Boston–based Intarcia Therapeutics' released positive early phase 3 results for ITCA 650, a once-a-year glucagon-like peptide-1 (GLP-1) treatment for diabetes type 2. Patients testing the GLP-1 receptor agonist exenatide under-the-skin minipump averaged a 2.5% drop in blood glucose after 13 weeks. This is a substantial reduction as the patients who enrolled in the trial had average A1C levels of 10–12% at the outset. Although the GLP-1 space is quite crowded, the convenience of Intarcia's once-a-year solution could give it an edge over its competitors. Sanofi and Medtronic formed an alliance to come up with type 2 diabetes therapies that improve patient adherence and simplify insulin treatment. The two giants will pool their human and financial resources in what they call an open-innovation model, uniting Sanofi's experience in diabetes drug development with Medtronic's heft in insulin-delivery devices and continuous glucose monitors.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Once-yearly diabetes drug. Nat Biotechnol 32, 709 (2014). https://doi.org/10.1038/nbt0814-709b

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0814-709b

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing